Table 2.
Recommended therapy management after index event
| Study population n = 72 | |
|---|---|
| No antiplatelet therapy | 9 (4.2%) |
| With OAC monotherapy | 6 |
| OAC + ASA | 3 (4.2%) |
| Without temporal recommendation | |
| OAC + Clopidogrel | 1 (1.4%) |
| With temporal recommendation for 3 months | |
| Monotherapy antiplatelet: | 28 (38.9%) |
| ASA | 25 (34.7%) |
| Without temporal recommendation | 24 |
| With temporal recommendation for 3 months | 1 |
| Clopidogrel | 2 (2.8%) |
| Without temporal recommendation | 1 |
| With temporal recommendation for 6 months | 1 |
| Ticagrelor | 1 (1.4%) |
| With temporal recommendation for 12 months | 1 |
| Dual antiplatelet therapy: | 29 (40.3%) |
| ASA + Clopidogrel | 24 (33.3%) |
| Without temporal recommendation | 5 |
| With temporal recommendation: | 19 |
| 1 month | 2 |
| 3 months | 4 |
| 6 months | 4 |
| 12 months | 8 |
| ASA + Prasugrel | 2 (2.8%) |
| Without temporal recommendation | 1 |
| With temporal recommendation for 12 months | 1 |
| ASA + Ticagrelor | 3 (4.2%) |
| Without temporal recommendation | 0 |
| With temporal recommendation | 3 |
| 1 month | 1 |
| 3 months | 1 |
| 12 months | 1 |
| “Triple” therapy with ASA | 2 (2.8%) |
| 1 month, Clopidogrel + OAC 6 months, OAC monotherapy | 1 |
| 1 month, Clopidogrel + OAK 12 months, OAC monotherapy | 1 |
Data is presented as number of patients and percentage
ASA Acetylsalicyl Acid, LWMH low weight molecular heparin, OAC oral anticoagulation